EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comorbidities and mutations including single‐ and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia—A population‐based study

Matilda Kjellander Kynning, Ebba Westerberg, Linda Forsell, Maria Creignou, Daniel Moreno Berggren, Bianca Tesi, Elsa Bernard, Elli Papaemmanuil, Yasuhito Nannya, Lucia Cavelier Franco, Davide Valentini, Eva Hellström Lindberg und 3 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Matilda Kjellander Kynning und 14 weiteren Autor:innen. Beteiligte Einrichtung: HERM, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic, DNA-Binding Proteins, Proto-Oncogene Proteins, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Karolinska Institutet, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To explore the relation between disease characteristics, comorbidities, mutations and overall survival (OS) in chronic myelomonocytic leukaemia (CMML), we collected data from a population‐based cohort of 149 consecutive patients. TET2 mutation ( TET2 MT ) was associated with higher haemoglobin, less leucocytosis and longer OS compared to no TET2 MT ( TET2 WT ), despite patients being significantly older. Patients with multihit TET2 MT had the most favourable outcome (HR 0.55, CI 0.35–0.88, p < 0.05). Multihit TET2 MT was associated with lower lactate dehydrogenase and less monocytosis, indicating multihit TET2 MT as a separate disease entity. Autoimmune disease (AID) was present in 33.6% of patients, with no association to any mutations. In multivariable analysis, the number of TET2 MT was demonstrated to be an independent factor associated with improved OS, and RUNX1 MT , myeloproliferative CMML (CMML‐MP), ECOG >0 and transfusion dependence remained significant adverse factors. Internal validation including cross‐validation and correction for optimism consistently demonstrated that a prognostic model containing the number of TET2 MT , RUNX1 , CMML‐MP, ECOG >0 and transfusion dependence showed better calibration, discrimination and overall performance than CPSS‐Mol in predicting OS. Importantly, the addition of TET2 mutation status to CPSS‐Mol also improved the CPSS‐Mol score performance. Taken together, TET2 MT status, especially multihit TET2 MT , defines a specific CMML phenotype and should be considered in future prognostic scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicDNA-Binding ProteinsProto-Oncogene ProteinsMutationHumansDioxygenasesMaleFemaleAgedMiddle AgedAged, 80 and overComorbidityPrognosisAdult

Stichwörter der Autor:innen

TET2autoimmune diseasecomorbiditiesthrombosis

Substanzen

DioxygenasesTET2 protein, humanDNA-Binding ProteinsProto-Oncogene Proteins

Autor:innen und Institutionen

  • HERM, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • ME Center for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden.
  • Hematology Unit, Akademiska University Hospital, Stockholm, Sweden.
  • Department of Medical Sciences, Section of Hematology, Uppsala University, Uppsala, Sweden.
  • Department of Clinical Genetics and Genomics, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Johanna Ungerstedt

Förderung

  • NCI NIH HHS
  • Karolinska Institutet
  • Cancerfonden
  • Radiumhemmets Forskningsfonder

Zitieren

APA

Kynning, M. K., Westerberg, E., Forsell, L., Creignou, M., Berggren, D. M., Tesi, B., Bernard, E., Papaemmanuil, E., Nannya, Y., Franco, L. C., Valentini, D., Lindberg, E. H., Ogawa, S., Ejerblad, E., & Ungerstedt, J. (2026). Comorbidities and mutations including single‐ and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia—A population‐based study. British Journal of Haematology. https://doi.org/10.1111/bjh.70264

Vancouver

Kynning MK, Westerberg E, Forsell L, Creignou M, Berggren DM, Tesi B, et al. Comorbidities and mutations including single‐ and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia—A population‐based study. British Journal of Haematology. 2026. doi:10.1111/bjh.70264

BibTeX
@article{Kynning2026,
  author = {Kynning, Matilda Kjellander and Westerberg, Ebba and Forsell, Linda and Creignou, Maria and Berggren, Daniel Moreno and Tesi, Bianca and Bernard, Elsa and Papaemmanuil, Elli and Nannya, Yasuhito and Franco, Lucia Cavelier and Valentini, Davide and Lindberg, Eva Hellström and Ogawa, Seishi and Ejerblad, Elisabeth and Ungerstedt, Johanna},
  title = {Comorbidities and mutations including single‐ and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia—A population‐based study},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70264}
}
Kostenlos starten →